<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>CardioBrief</title>
	<atom:link href="http://cardiobrief.org/feed/" rel="self" type="application/rss+xml" />
	<link>http://cardiobrief.org</link>
	<description>One-stop source for cardiology news and links</description>
	<lastBuildDate>Thu, 31 May 2012 02:57:20 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='cardiobrief.org' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://1.gravatar.com/blavatar/5706effc1b2c62d7b9c46c6c74eb5d86?s=96&#038;d=http%3A%2F%2Fs2.wp.com%2Fi%2Fbuttonw-com.png</url>
		<title>CardioBrief</title>
		<link>http://cardiobrief.org</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="http://cardiobrief.org/osd.xml" title="CardioBrief" />
	<atom:link rel='hub' href='http://cardiobrief.org/?pushpress=hub'/>
		<item>
		<title>Fascinating Debate Over Statins For Primary Prevention</title>
		<link>http://cardiobrief.org/2012/05/30/fascinating-debate-over-statins-for-primary-prevention/</link>
		<comments>http://cardiobrief.org/2012/05/30/fascinating-debate-over-statins-for-primary-prevention/#comments</comments>
		<pubDate>Wed, 30 May 2012 17:20:17 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[primary prevention]]></category>
		<category><![CDATA[statins]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11639</guid>
		<description><![CDATA[The recent guest post by David Newman has prompted several thought-provoking comments. Since most readers will likely miss the comments, I&#8217;ve moved these comments to a separate post. Statin Island May 27, 2012, 3:35 PM: Thank you. Clearly, this important commentary raises questions about the integrity of Lancet as well as the authors of the study. But what is most discouraging, and dangerous, is that this kind of deception occurs so frequently. Meanwhile, major news outlets, television channels, etc. have reported the results as the authors intended. And so the gravy train has left the station. Lancet <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/30/fascinating-debate-over-statins-for-primary-prevention/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11639&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/30/fascinating-debate-over-statins-for-primary-prevention/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Guest Post: Data, Drugs, And Deception&#8211; A True Story</title>
		<link>http://cardiobrief.org/2012/05/27/guest-post-data-drugs-and-deception-a-true-story/</link>
		<comments>http://cardiobrief.org/2012/05/27/guest-post-data-drugs-and-deception-a-true-story/#comments</comments>
		<pubDate>Sun, 27 May 2012 19:05:02 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[metaanalysis]]></category>
		<category><![CDATA[primary prevention]]></category>
		<category><![CDATA[statins]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11635</guid>
		<description><![CDATA[Editor’s Note: The following guest post by Dr. David Newman is reprinted with permission from his website and blog, Smartem.Org. Dr. Newman is an Emergency Physician and Director of Clinical Research at Mt. Sinai School of Medicine in the Department of Emergency Medicine.  He is the author of the critically-acclaimed Hippocrates’ Shadow: Secrets From the House of Medicine. CardioBrief readers might also enjoy watching his TED talk, Truth That Lasts. Data, Drugs, And Deception&#8211; A True Story by Dr. David Newman Last week The Lancet published a meta-analysis of 27 statin trials, an attempt to determine whether patients with no history <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/27/guest-post-data-drugs-and-deception-a-true-story/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11635&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/27/guest-post-data-drugs-and-deception-a-true-story/feed/</wfw:commentRss>
		<slash:comments>10</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Aspirin Found To Prevent Recurrent Venous Thromboembolism</title>
		<link>http://cardiobrief.org/2012/05/24/aspirin-found-to-prevent-recurrent-venous-thromboembolism/</link>
		<comments>http://cardiobrief.org/2012/05/24/aspirin-found-to-prevent-recurrent-venous-thromboembolism/#comments</comments>
		<pubDate>Thu, 24 May 2012 15:08:52 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[anticoagulation therapy]]></category>
		<category><![CDATA[aspirin]]></category>
		<category><![CDATA[oral anticoagulation]]></category>
		<category><![CDATA[venous thromboembolism]]></category>
		<category><![CDATA[VTE]]></category>
		<category><![CDATA[warfarin]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11632</guid>
		<description><![CDATA[Aspirin can help prevent the recurrence of venous thromboembolism (VTE) after discontinuation of anticoagulation therapy, according to results of the WARFASA (the Warfarin and Aspirin) study published in the New England Journal of Medicine. Following 6 to 18 months of oral anticoagulation, 403 patients with first-time unprovoked VTE were randomized to aspirin (100 mg daily) or placebo for two years. Aspirin therapy resulted in a significant reduction in VTE but did not cause an increase in the risk of bleeding: VTE recurrence: 6.6% per year in the aspirin group versus 11.2% in the placebo group (hazard ratio <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/24/aspirin-found-to-prevent-recurrent-venous-thromboembolism/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11632&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/24/aspirin-found-to-prevent-recurrent-venous-thromboembolism/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA Advisory Committee Recommends Against ACS Indication For Rivaroxaban</title>
		<link>http://cardiobrief.org/2012/05/23/fda-advisory-committee-recommends-against-acs-indication-for-rivaroxaban/</link>
		<comments>http://cardiobrief.org/2012/05/23/fda-advisory-committee-recommends-against-acs-indication-for-rivaroxaban/#comments</comments>
		<pubDate>Wed, 23 May 2012 21:22:18 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[fda panel]]></category>
		<category><![CDATA[rivaroxaban]]></category>
		<category><![CDATA[Xarelto]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11627</guid>
		<description><![CDATA[The FDA&#8217;s Cardiovascular and Renal Drugs Advisory Committee voted against adding an indication for acute coronary syndromes (ACS) to the label  of the anticoagulant rivaroxaban (Xarelto). The vote was 6 to 4 against approval, with 1 abstention. The advisory panel spent most of the day trying to reconcile diametrically opposed views of the pivotal ATLAS ACS 2-TIMI 51 trial. On the one hand, the sponsor (Johnson &#38; Johnson) and the TIMI investigators (Jessica Mega, C. Michael Gibson, and Eugene Braunwald) portrayed a robustly positive trial that strongly demonstrated the beneficial effects of low dose rivaroxaban in ACS when <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/23/fda-advisory-committee-recommends-against-acs-indication-for-rivaroxaban/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11627&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/23/fda-advisory-committee-recommends-against-acs-indication-for-rivaroxaban/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Live Blog: The FDA Advisory Panel For Rixaroxaban for ACS</title>
		<link>http://cardiobrief.org/2012/05/23/live-blog-the-fda-advisory-panel-for-rixaroxaban-for-acs/</link>
		<comments>http://cardiobrief.org/2012/05/23/live-blog-the-fda-advisory-panel-for-rixaroxaban-for-acs/#comments</comments>
		<pubDate>Wed, 23 May 2012 12:01:07 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[MI/ACS]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[fda panel]]></category>
		<category><![CDATA[rivaroxaban]]></category>
		<category><![CDATA[Xarelto]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11534</guid>
		<description><![CDATA[Here&#8217;s my live-blogg of the FDA&#8217;s Cardiovascular and Renal Drugs Advisory Committee meeting to consider the supplemental new drug application (sNDA) for rivaroxaban (Xarelto, Johnson &#38; Johnson) for use in patients with acute coronary syndrome (ACS) already taking dual antiplatelet therapy. Here is a link to the FDA briefing documents. ========================= 4:48: Meeting adjourned! J&#38;J has just issued a press release saying they will &#8220;ensure the questions raised today are addressed with the FDA.&#8221; 4:45: Temple is raising the possibility that the FDA might ultimately approve rivaroxaban for ACS. I would not be shocked if this were to happen. 4:38: Now discussing whether <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/23/live-blog-the-fda-advisory-panel-for-rixaroxaban-for-acs/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11534&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/23/live-blog-the-fda-advisory-panel-for-rixaroxaban-for-acs/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Studies Probe Effect Of CPAP And Sleep Apnea On Hypertension</title>
		<link>http://cardiobrief.org/2012/05/22/studies-probe-effect-of-cpap-and-sleep-apnea-on-hypertesnion/</link>
		<comments>http://cardiobrief.org/2012/05/22/studies-probe-effect-of-cpap-and-sleep-apnea-on-hypertesnion/#comments</comments>
		<pubDate>Tue, 22 May 2012 20:02:38 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[CPAP]]></category>
		<category><![CDATA[hypertension]]></category>
		<category><![CDATA[obstructive sleep apnea]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11528</guid>
		<description><![CDATA[Two studies published in JAMA provide additional but not surprising information about the relationship between obstructive sleep apnea (OSA), hypertension, and the role of continuous positive airway pressure (CPAP). In the first study, Ferran Barbé and colleagues randomized 725 people with OSA but no daytime sleepiness to either CPAP or no active treatment. Although there were fewer cases of systemic hypertension or cardiovascular events in the CPAP group than in the control group after a median followup of 4 years, this difference did not reach significance. Incidence of hypertension or cardiovascular events: CPAP: 9.20 per 100 <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/22/studies-probe-effect-of-cpap-and-sleep-apnea-on-hypertesnion/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11528&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/22/studies-probe-effect-of-cpap-and-sleep-apnea-on-hypertesnion/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Rivaroxaban For ACS Gets Positive FDA Review, But Questions About ATLAS Trial Conduct Persist</title>
		<link>http://cardiobrief.org/2012/05/21/rivaroxaban-for-acs-gets-positive-fda-review-but-questions-about-atlas-trial-conduct-persist/</link>
		<comments>http://cardiobrief.org/2012/05/21/rivaroxaban-for-acs-gets-positive-fda-review-but-questions-about-atlas-trial-conduct-persist/#comments</comments>
		<pubDate>Mon, 21 May 2012 18:25:19 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[MI/ACS]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[fda panel]]></category>
		<category><![CDATA[rivaroxaban]]></category>
		<category><![CDATA[Xarelto]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11524</guid>
		<description><![CDATA[The FDA will offer generally positive but also highly mixed advice to the FDA&#8217;s Cardiovascular and Renal Drugs Advisory Committee  when it meets on Wednesday to consider the supplemental new drug application for rivaroxaban (Xarelto, Johnson &#38; Johnson) for use in patients with acute coronary syndrome (ACS) already taking dual antiplatelet therapy. The FDA posted the briefing documents on its website this morning. Although the primary clinical review and the statistical review support approval for the new indication (the drug is already approved for venous thromboembolism prophylaxis and stroke prevention in AF), one reviewer, Thomas Marciniak, the Medical <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/21/rivaroxaban-for-acs-gets-positive-fda-review-but-questions-about-atlas-trial-conduct-persist/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11524&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/21/rivaroxaban-for-acs-gets-positive-fda-review-but-questions-about-atlas-trial-conduct-persist/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>You Know Nothing, Dr. Snow: Why Medicine Can&#8217;t Be More Like Facebook</title>
		<link>http://cardiobrief.org/2012/05/18/you-know-nothing-dr-snow-why-medicine-cant-be-more-like-facebook/</link>
		<comments>http://cardiobrief.org/2012/05/18/you-know-nothing-dr-snow-why-medicine-cant-be-more-like-facebook/#comments</comments>
		<pubDate>Fri, 18 May 2012 19:01:20 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[azithromycin]]></category>
		<category><![CDATA[cholesterol]]></category>
		<category><![CDATA[coffee]]></category>
		<category><![CDATA[Facebook]]></category>
		<category><![CDATA[HDL]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[statins]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11506</guid>
		<description><![CDATA[Medicine can never be like Facebook, despite what Matt Herper argues over at Forbes. Perhaps he was just trolling for hits on a day when everyone is thinking about the Facebook IPO, but Herper proposed, with apparently seriousness, that medicine needs to model itself on the tech world in order to match the kind of progress&#8211; and profits&#8211; of a Facebook. But the medical news this week provided ample evidence why this will never happen. Biology is much more complex and resistant than the digital world. For a medical journalist like myself this was a <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/18/you-know-nothing-dr-snow-why-medicine-cant-be-more-like-facebook/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11506&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/18/you-know-nothing-dr-snow-why-medicine-cant-be-more-like-facebook/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA Approves Generic Clopidogrels As Plavix Loses Patent Protection</title>
		<link>http://cardiobrief.org/2012/05/17/fda-approves-generic-clopidogrels-as-plavix-loses-patent-protection/</link>
		<comments>http://cardiobrief.org/2012/05/17/fda-approves-generic-clopidogrels-as-plavix-loses-patent-protection/#comments</comments>
		<pubDate>Thu, 17 May 2012 19:10:26 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Brilinta]]></category>
		<category><![CDATA[clopidogrel]]></category>
		<category><![CDATA[Effient]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Plavix]]></category>
		<category><![CDATA[prasugrel]]></category>
		<category><![CDATA[ticagrelor]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11503</guid>
		<description><![CDATA[For the second time in the past six months, a cardiology mainstay drug has lost patent protection and gone generic. Today the FDA announced that it had approved several generic versions of clopidogrel (Plavix), the antiplatelet drug that for many years was the second best-selling drug in the world. Last November the best-selling drug of all time, Lipitor (atorvastatin), another cardiology mainstay, went off patent, though it wasn&#8217;t until earlier this month that multiple generics became available. The FDA said that it had approved 300 mg formulations of clopdiogrel from Gate Pharmaceuticals, Mylan Pharmaceuticals, and Teva Pharmaceuticals and <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/17/fda-approves-generic-clopidogrels-as-plavix-loses-patent-protection/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11503&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/17/fda-approves-generic-clopidogrels-as-plavix-loses-patent-protection/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Large Metaanalysis Finds Statins Effective in Low Risk Patients</title>
		<link>http://cardiobrief.org/2012/05/16/large-metaanalysis-statins-effective-in-low-risk-patients/</link>
		<comments>http://cardiobrief.org/2012/05/16/large-metaanalysis-statins-effective-in-low-risk-patients/#comments</comments>
		<pubDate>Wed, 16 May 2012 23:40:29 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[cholesterol]]></category>
		<category><![CDATA[LDL]]></category>
		<category><![CDATA[statins]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=11475</guid>
		<description><![CDATA[A very large metaanalysis provides strong evidence that the relative reduction in risk of statins is at least as great in low-risk patients as in high-risk patients. The finding, write the authors, provides evidence that expansion of guidelines to lower risk populations should be considered. In their paper in the Lancet, the  the Cholesterol Treatment Trialists’ (CTT) Collaborators analyzed data from 134,537 patients in trials comparing statins to control therapy and 39,612 patients in trials comparing low and high dose statins. They examined the impact of statin therapy according to the baseline 5-year risk of a major vascular <a class="entry-excerpt-link" href="http://cardiobrief.org/2012/05/16/large-metaanalysis-statins-effective-in-low-risk-patients/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=11475&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2012/05/16/large-metaanalysis-statins-effective-in-low-risk-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://1.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
	</channel>
</rss>
